A 6-month interruption of antiretroviral therapy improves adipose tissue function in HIV-infected patients: The ANRS EP29 Lipostop Study

Antiviral Therapy

Volumn 12, Issue 8, 2007, Pages 1273-1283

  Min, Ji Kim ^a,b   Leclercq, Pascale ^c   Lanoy, Emilie ^a,b   Cervera, Pascale ^a,b   Antuna Puente, Barbara ^a,b,d   Maachi, Mustapha ^a,b,d   Dorofeev, Elena ^a,b   Slama, Laurence ^d   Valantin, Marc Antoine ^e   Costagliola, Dominique ^a,b   Lombes, Anne ^a,b   Bastard, Jean Philippe ^a,b,d   Capeau, Jacqueline ^a,b,d  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d HÔPITAL TENON   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANTIRETROVIRUS AGENT; ATAZANAVIR; CHLORDANE; CYTOCHROME C OXIDASE; EFAVIRENZ; INDINAVIR; INTERLEUKIN 6; LOPINAVIR; MESSENGER RNA; MITOCHONDRIAL DNA; NELFINAVIR; NEVIRAPINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; RITONAVIR; SAQUINAVIR; STAVUDINE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; ZIDOVUDINE;

ABDOMINAL SUBCUTANEOUS FAT; ADIPOCYTE; ADIPOSE TISSUE; ADULT; ANTIVIRAL THERAPY; ARTICLE; BIOGENESIS; BODY FAT DISTRIBUTION; CELL DIFFERENTIATION; CELL FUNCTION; CELL INFILTRATION; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG WITHDRAWAL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LABORATORY TEST; MACROPHAGE; MALE; NEEDLE BIOPSY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

ADIPOSE TISSUE; ADULT; ANTI-RETROVIRAL AGENTS; BIOPSY; DNA, MITOCHONDRIAL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INFLAMMATION; INTERLEUKIN-6; MACROPHAGES; MALE; MITOCHONDRIA; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; WITHHOLDING TREATMENT;

EID: 38049072577     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352:48-62.
2. Nolan D, Mallal S. Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanisms. Antivir Ther 2004; 9:849-863.
3. Gougeon ML, Penicaud L, Fromenty B, Leclercq P, Viard JP, Capeau J. Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations. Antivir Ther 2004; 9:161-177.
4. Villaroya F, Domingo P, Giralt M. Lipodystrophy associated with highly active antiretroviral therapy for HIV infection: the adipocyte as a target of antiretroviral-induced mitochondrial toxicity. Trends Pharmacol Sci 2005; 26:88-93.
5. Saves M, Chene G, Ducimetiere P, et al. Risk Factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. CID 2003; 37:292-297.
6. Nolan D, Hammond E, James I, et al. Contribution of nucleoside-analogue reverse trancriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antivir Ther 2003; 8:617-626.
7. Noor MA, Lo JC, Mulligan K, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001; 15:F11-18.
8. Noor MA, Flint O, Maa JF, et al. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS 2006; 20:1813-1821.
9. Jemsek J, Arathoon E, Arlotti M et al. Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients. CID 2005; 42:273-280.
10. Haubrich R, Riddler S, DiRienzo G, et al. Metabolic outcomes of ACTG 5142: a prospective, randomized, phase 111 trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection. 14th Conference on Retroviruses & Opportunistic Infections. 26-28 February 2007, Los Angeles, CA, USA. Oral Abstract 38.
11. Gallant JE, Staszewski S, Pozniak A, et al. Efficacy and safety of tenofivir DF vs stavudine in combination therapy in antiretroviral-naive patients. JAMA 2004; 292:191-201.
12. Podzamczer D, Ferrer E, Sanchez P, et al. Less lipoathorphy and better lipid profile with abacavir as compared to stavudine. J Acquir Immune Defic Syndr 2007; 44:139-147.
13. Ben-Romano R, Rudich A, Etzion S, et al. Nelfinavir induces adipocyte insulin resistance through the induction of oxidative stress: differential protective effect of antioxidant agents. Antivir Ther 2006; 11:1051-1060.
14. Lagathu C, Kim M, Maachi M, et al. HIV antiretroviral treatment alters adipokine expression and insulin sensitivity of adipose tissue in vitro and in vivo. Biochimie 2005; 87:65-71.
15. Lagathu C, Bastard JP, Auclair M, et al. Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro. Antivir Ther 2004; 9:911-920.
16. Lagathu C, Eustace B, Frantz D, et al. Some HIV-antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir Ther 2007; 12:489-500.
17. Boccara F, Caron M, Auclair, et al. Irbesartan, an angiotensin II receptor I blocker, prevents the adverse efects of HIV antiretrovirals on adipocyte functions. Antivir Ther 2006; 11:L7.
18. Caron M, Auclair M, Lagathu C, et al. The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro. AIDS 2004; 18:2127-2136.
19. El Hadri K, Glorian M, Monsempes C, et al. In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3t3 and human preadipocytes or adipocytes. J Biol Chem 2004; 279:15130-15141.
20. Bastard JP, Caron M, Vidal H, et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002; 359:1026-1031.
21. Lloreta J, Domingo P, Pujol RM, et al. Ultrastructural features of highly active antiretroviral therapy-associated partial lipodystrophy. Virchows Arch 2002; 441:599-604.
22. Pace CS, Martin AM, Hammond EL, Mamotte CD, Nolan DA, Mallal SA. Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients. Antivir Ther 2003; 8:323-331.
23. Jan V, Cervera P, Maachi M, et al. Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV-1-infected lipodystrophic patients. Antivir Ther 2004; 9:555-564.
24. McComsey GA, Paulsen DM, Lonergan JT, et al. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS 2005; 19:15-23.
25. Kannisto K, Sutinen J, Korsheninnikova E, et al. Expression of adipogenic transcription factors, peroxisome proliferator-activated receptor gamma co-activator 1, IL-6 and CD45 in subcutaneous adipose tissue in lipodystrophy associated with highly active antiretroviral therapy. AIDS 2003; 17:1753-1762.
26. Martin A, Smith DE, Carr A, et al. Mitochondrial Toxicity Study Group. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 2004; 18:1029-1036.
27. Moyle GJ, Sabin CA, Cartledge J, et al. RAVE (Randomized Abacavir versus Viread Evaluation) Group UK. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006; 20:2043-2050.
28. Strategies for the management of antiretroviral therapy (SMART) study group, El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4* count-guided interruption of antiretroviral treatment: SMART study. N Engl J Med 2006; 355:2283-2296.
29. Lihn AS, Richelsen B, Pedersen SB, et al. Increased expression of TNF-α, IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels. Am J Physiol Endocrinol Metab 2003; 285:E1072-1080.
30. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112:1796-1808.
31. Jones SP, Qazi N, Morelese J, et al. Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens. J Acquir Immune Defic Syndr 2005; 40:565-572.
32. Chaparro J, Reeds DN, Wen W, et al. Alterations in thigh subcutaneous adipose tissue gene expression in protease inhibitor-based highly active antiretroviral therapy. Metabolism 2005; 54:561-567.
33. Mallon PW, Unemori P, Sedwell R, et al. In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. J Infect Dis 2005; 191:1686-1696.
34. Noor MA, Parker RA, O'Mara E, et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 2004; 18:2137-2144.
35. Kim MJ, Jardel C, Barthélémy C, et al. Preserved cytochrome c oxidase activity despite mtDNA depletion in adipose tissue of HIV-infected patients with lipodystrophy Antivir Ther 2005; 10 Suppl 3:L8.
36. Caron M, Auclair M, Donadille B, et al. Lipodystrophies linked to HIV protease inhibitor therapy and mutations in A type lamins are both associated with prelamin A accumulation and premature senescence. Antivir Ther 2006; 11:L30.